Funding of Parkinson Research from Industry and US Federal and Foundation Sources
Identifieur interne : 000E71 ( PascalFrancis/Checkpoint ); précédent : 000E70; suivant : 000E72Funding of Parkinson Research from Industry and US Federal and Foundation Sources
Auteurs : E. Ray Dorsey [États-Unis] ; Joel P. Thompson [États-Unis] ; Mark Frasier [États-Unis] ; Todd Sherer [États-Unis] ; Brian Fiske [États-Unis] ; Sean Nicholson [États-Unis] ; S. Claiborne Johnston [États-Unis] ; Robert G. Holloway [États-Unis] ; Hamilton Iii Moses [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:09-0218143Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Funding of Parkinson Research from Industry and US Federal and Foundation Sources</title><author><name sortKey="Dorsey, E Ray" sort="Dorsey, E Ray" uniqKey="Dorsey E" first="E. Ray" last="Dorsey">E. Ray Dorsey</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester Medical Center</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Thompson, Joel P" sort="Thompson, Joel P" uniqKey="Thompson J" first="Joel P." last="Thompson">Joel P. Thompson</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences</s1><s2>Buffalo, New York</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Frasier, Mark" sort="Frasier, Mark" uniqKey="Frasier M" first="Mark" last="Frasier">Mark Frasier</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1><s2>New York, New York</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Sherer, Todd" sort="Sherer, Todd" uniqKey="Sherer T" first="Todd" last="Sherer">Todd Sherer</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1><s2>New York, New York</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Fiske, Brian" sort="Fiske, Brian" uniqKey="Fiske B" first="Brian" last="Fiske">Brian Fiske</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1><s2>New York, New York</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Nicholson, Sean" sort="Nicholson, Sean" uniqKey="Nicholson S" first="Sean" last="Nicholson">Sean Nicholson</name><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Policy Analysis and Management, Cornell University</s1><s2>Ithaca, New York</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region><settlement type="city">Ithaca (New York)</settlement></placeName><orgName type="university">Université Cornell</orgName></affiliation></author><author><name sortKey="Claiborne Johnston, S" sort="Claiborne Johnston, S" uniqKey="Claiborne Johnston S" first="S." last="Claiborne Johnston">S. Claiborne Johnston</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Neurology, University of California</s1><s2>San Francisco, California</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Holloway, Robert G" sort="Holloway, Robert G" uniqKey="Holloway R" first="Robert G." last="Holloway">Robert G. Holloway</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester Medical Center</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Moses, Hamilton Iii" sort="Moses, Hamilton Iii" uniqKey="Moses H" first="Hamilton Iii" last="Moses">Hamilton Iii Moses</name><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>The Alerion Institute</s1><s2>North Garden, Virginia</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Virginie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0218143</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0218143 INIST</idno><idno type="RBID">Pascal:09-0218143</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F19</idno><idno type="wicri:Area/PascalFrancis/Curation">001E00</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000E71</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Funding of Parkinson Research from Industry and US Federal and Foundation Sources</title><author><name sortKey="Dorsey, E Ray" sort="Dorsey, E Ray" uniqKey="Dorsey E" first="E. Ray" last="Dorsey">E. Ray Dorsey</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester Medical Center</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Thompson, Joel P" sort="Thompson, Joel P" uniqKey="Thompson J" first="Joel P." last="Thompson">Joel P. Thompson</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences</s1><s2>Buffalo, New York</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Frasier, Mark" sort="Frasier, Mark" uniqKey="Frasier M" first="Mark" last="Frasier">Mark Frasier</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1><s2>New York, New York</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Sherer, Todd" sort="Sherer, Todd" uniqKey="Sherer T" first="Todd" last="Sherer">Todd Sherer</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1><s2>New York, New York</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Fiske, Brian" sort="Fiske, Brian" uniqKey="Fiske B" first="Brian" last="Fiske">Brian Fiske</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1><s2>New York, New York</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Nicholson, Sean" sort="Nicholson, Sean" uniqKey="Nicholson S" first="Sean" last="Nicholson">Sean Nicholson</name><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Policy Analysis and Management, Cornell University</s1><s2>Ithaca, New York</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region><settlement type="city">Ithaca (New York)</settlement></placeName><orgName type="university">Université Cornell</orgName></affiliation></author><author><name sortKey="Claiborne Johnston, S" sort="Claiborne Johnston, S" uniqKey="Claiborne Johnston S" first="S." last="Claiborne Johnston">S. Claiborne Johnston</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Neurology, University of California</s1><s2>San Francisco, California</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Holloway, Robert G" sort="Holloway, Robert G" uniqKey="Holloway R" first="Robert G." last="Holloway">Robert G. Holloway</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester Medical Center</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Moses, Hamilton Iii" sort="Moses, Hamilton Iii" uniqKey="Moses H" first="Hamilton Iii" last="Moses">Hamilton Iii Moses</name><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>The Alerion Institute</s1><s2>North Garden, Virginia</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Virginie</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Industry</term><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Industrie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>24</s2></fA05><fA06><s2>5</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Funding of Parkinson Research from Industry and US Federal and Foundation Sources</s1></fA08><fA11 i1="01" i2="1"><s1>DORSEY (E. Ray)</s1></fA11><fA11 i1="02" i2="1"><s1>THOMPSON (Joel P.)</s1></fA11><fA11 i1="03" i2="1"><s1>FRASIER (Mark)</s1></fA11><fA11 i1="04" i2="1"><s1>SHERER (Todd)</s1></fA11><fA11 i1="05" i2="1"><s1>FISKE (Brian)</s1></fA11><fA11 i1="06" i2="1"><s1>NICHOLSON (Sean)</s1></fA11><fA11 i1="07" i2="1"><s1>CLAIBORNE JOHNSTON (S.)</s1></fA11><fA11 i1="08" i2="1"><s1>HOLLOWAY (Robert G.)</s1></fA11><fA11 i1="09" i2="1"><s1>MOSES (Hamilton III)</s1></fA11><fA14 i1="01"><s1>Department of Neurology, University of Rochester Medical Center</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="02"><s1>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences</s1><s2>Buffalo, New York</s2><s3>USA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1><s2>New York, New York</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Policy Analysis and Management, Cornell University</s1><s2>Ithaca, New York</s2><s3>USA</s3><sZ>6 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Neurology, University of California</s1><s2>San Francisco, California</s2><s3>USA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="06"><s1>The Alerion Institute</s1><s2>North Garden, Virginia</s2><s3>USA</s3><sZ>9 aut.</sZ></fA14><fA20><s1>731-737</s1></fA20><fA21><s1>2009</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000186090170150</s5></fA43><fA44><s0>0000</s0><s1>© 2009 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>36 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>09-0218143</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Industrie</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Industry</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Industria</s0><s5>09</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>159</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Virginie</li><li>État de New York</li></region><settlement><li>Ithaca (New York)</li></settlement><orgName><li>Université Cornell</li></orgName></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Dorsey, E Ray" sort="Dorsey, E Ray" uniqKey="Dorsey E" first="E. Ray" last="Dorsey">E. Ray Dorsey</name></region><name sortKey="Claiborne Johnston, S" sort="Claiborne Johnston, S" uniqKey="Claiborne Johnston S" first="S." last="Claiborne Johnston">S. Claiborne Johnston</name><name sortKey="Fiske, Brian" sort="Fiske, Brian" uniqKey="Fiske B" first="Brian" last="Fiske">Brian Fiske</name><name sortKey="Frasier, Mark" sort="Frasier, Mark" uniqKey="Frasier M" first="Mark" last="Frasier">Mark Frasier</name><name sortKey="Holloway, Robert G" sort="Holloway, Robert G" uniqKey="Holloway R" first="Robert G." last="Holloway">Robert G. Holloway</name><name sortKey="Moses, Hamilton Iii" sort="Moses, Hamilton Iii" uniqKey="Moses H" first="Hamilton Iii" last="Moses">Hamilton Iii Moses</name><name sortKey="Nicholson, Sean" sort="Nicholson, Sean" uniqKey="Nicholson S" first="Sean" last="Nicholson">Sean Nicholson</name><name sortKey="Sherer, Todd" sort="Sherer, Todd" uniqKey="Sherer T" first="Todd" last="Sherer">Todd Sherer</name><name sortKey="Thompson, Joel P" sort="Thompson, Joel P" uniqKey="Thompson J" first="Joel P." last="Thompson">Joel P. Thompson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E71 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000E71 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:09-0218143
|texte= Funding of Parkinson Research from Industry and US Federal and Foundation Sources
}}
| This area was generated with Dilib version V0.6.23. |  |